Ono chases Takeda in polycythemia
Ono's antisense therapy is to begin its first pivotal trial.
Rusfertide still needs to be Verified
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
Ono takes on Takeda in polycythemia vera
The Japanese group licenses sapablursen from Ionis for $280m.
Protagonist Verifies Takeda’s interest
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
Takeda taps Protagonist before it’s Verified
Rusfertide’s big readout will now not come until 2025.
